+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Gastroparesis Drug Market - Growth, Trends, and Forecast (2020 - 2025)

  • ID: 5025972
  • Report
  • May 2020
  • Region: Global
  • 117 pages
  • Mordor Intelligence
1 of 5

Enquire about COVID-19 updates for this product.

Enquire Now


  • Allergan Plc
  • AstraZeneca Plc
  • Bausch Health
  • Cadila Pharmaceuticals
  • Evoke Pharma
  • GlaxoSmithKline plc.
  • MORE
The gastroparesis drug market is expected to register a CAGR of 4.5% during the forecast period. Several factors such as the increase in the incidence rate of diabetic population, rise in the number of surgical procedures and growth in geriatric population are among the key driving factors for the gastroparesis drug market. Gastroparesis is a disorder affecting mostly type1 and type2 diabetic patients. In this disorder, the stomach takes too long to empty its contents. Drugs such as erythromycin, antiemetics, and Reglan are prescribed for treating gastroparesis. Moreover, there are 119 completed and ongoing clinical trials for gastroparesis drugs due to high prevalence of type1 and type2 diabetes which may further have high chances of having gastroparesis. This drives the demand for these drugs and will further fuel the overall market to a certain extent. However, side effects related to gastroparesis drugs may hamper the market.

Key Market Trends

Idiopathic Gastroparesis Segment is Expected to Contribute a largest segment in the Gastroparesis Drug Market.
  • Idiopathic gastroparesis is growing at a good rate as this disease is a very common category in gastroparesis wherein cause is unknown and symptoms are vomiting, nausea, upper abdominal pain. These symptoms can be cured by dietary modification, antiemetic drug therapy, prokinetics medication, and symptoms modulators. This further results in the adoption of gastroparesis drugs and will drive the market to a certain extent. Prokinetics drugs will also enhance the gastrointestinal motility by increasing the frequency of contraction and propel the growth of gastroparesis drug market.
  • In addition, with the growing number of diabetes Mellitus population worldwide, leading to high demand for diagnosis and treatment and as diabetes is a common cause of gastroparesis condition so thus propel the gastroparesis drug market
North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period

North America expected to hold a major market share in the Gastroparesis Drug market due to the increasing aging population and the rising number of surgical procedures. For instance, according to the Centers for Disease Control and Prevention in 2019 around 84 million people have prediabetics which leading to the prevalence of gastroparesis disorder and will drive the gastroparesis drug market. Furthermore, increasing healthcare expenditure, a growing number of hospitals and the presence of well-established healthcare infrastructure is also fueling the growth of the overall regional market to a large extent.

Asia- Pacific regions will also show a lucrative opportunity for many companies as countries like India has a high prevalence rate of diabetes which further leads to gastroparesis disorder and will contribute to the gastroparesis drug market.

Competitive Landscape

Some of the companies which are currently dominating the market are Abbott (Abbott Arzneimittel GmbH), Allergan, Cadila Pharmaceuticals, Evoke Pharma, AstraZeneca, Neurogastrx, Inc, Bausch Health, Theravance Biopharma, and GlaxoSmithKline plc.

Reasons to Purchase this report:
  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

This report will be delivered within 2 business days.
Note: Product cover images may vary from those shown
2 of 5


  • Allergan Plc
  • AstraZeneca Plc
  • Bausch Health
  • Cadila Pharmaceuticals
  • Evoke Pharma
  • GlaxoSmithKline plc.
  • MORE
1.1 Study Assumptions
1.2 Scope of the Study



4.1 Market Overview
4.2 Market Drivers
4.2.1 Increase in the Incidence Rate of Diabetes
4.2.2 Rise in Number of Surgeries
4.2.3 Growth in Geriatric Population
4.3 Market Restraints
4.3.1 Time-consuming regulatory process
4.3.2 Side effects of gastroparesis drugs
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5.1 By Drug Class
5.1.1 Antiemetic Agents
5.1.2 Prokinetic Agents
5.1.3 Botulinum Toxin Injections
5.2 By Disease Type
5.2.1 Diabetic Gastroparesis
5.2.2 Post-Surgical Gastroparesis
5.2.3 Idiopathic Gastroparesis
5.2.4 Others
5.3 By End User
5.3.1 Hospitals
5.3.2 Clinics
5.3.3 Pharmacies
5.4 Geography
5.4.1 North America United States Canada Mexico
5.4.2 Europe Germany United Kingdom France Italy Spain Rest of Europe
5.4.3 Asia-Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.4.4 Middle-East and Africa GCC South Africa Rest of Middle-East and Africa
5.4.5 South America Brazil Argentina Rest of South America

6.1 Company Profiles
6.1.1 Abbott (Abbott Arzneimittel GmbH)
6.1.2 Allergan Plc
6.1.3 Cadila Pharmaceuticals
6.1.4 Evoke Pharma
6.1.5 AstraZeneca Plc
6.1.6 Neurogastrx, Inc
6.1.7 Bausch Health
6.1.8 Theravance Biopharma
6.1.9 GlaxoSmithKline plc.

Note: Product cover images may vary from those shown
3 of 5


4 of 5
  • Abbott (Abbott Arzneimittel GmbH)
  • Allergan Plc
  • Cadila Pharmaceuticals
  • Evoke Pharma
  • AstraZeneca Plc
  • Neurogastrx, Inc
  • Bausch Health
  • Theravance Biopharma
  • GlaxoSmithKline plc.
Note: Product cover images may vary from those shown
5 of 5